SOURCE: Protherics PLC

October 08, 2007 13:13 ET

Protherics PLC - Block Listing Return - 2

Cheshire, UK--(Marketwire - October 8, 2007) -

                                 Protherics PLC
                         6 monthly Block Listing Return
                         Unapproved Share Option Scheme
London, UK; Brentwood, TN; 8 October 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, today, the following 6 monthly block listing return in respect of the Company's Unapproved Share Option Scheme has been lodged with the FSA in accordance with Listing Rule 3.5.6.
Name of applicant:                     Protherics PLC

Name of scheme:                        Protherics PLC Unapproved Share
                                       Option Scheme

Period of return:                      From:    9 April 2007
                                       To:      8 October 2007
Balance under scheme from 
previous return:                       3,151,947

The amount by which the block 
scheme has been increased, if the 
scheme has been increased since 
the date of the last return:           Nil

Number of securities issued/allotted 
under scheme during period:            25,000

Balance under scheme not yet 
issued/allotted at end of period:      3,126,947

Number and class of securities 
originally listed and the  
date of admission:                     4,559,122 Ordinary Shares 
                                       (date of admission: 8 April 2005)
Total number of securities in issue 
at the end of the period:              339,346,822

                                    Ends  

For further information please contact:

Protherics
Nick Staples, Director of 
Corporate Affairs                             +44 (0) 7919  480510
Julie Vickers, Company Secretary              +44 (0) 1928  518010

Financial Dynamics - press enquiries
London: Ben Atwell, David Yates               +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt       +1 212 850 5600

Or visit  www.protherics.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange